IP Verse

Alnylam Pharmaceuticals competitive analysis

Loading summary...

Latest oppositions filed by Alnylam Pharmaceuticals

Explore patent oppositions filed by Alnylam Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP2978451
Compositions And Methods For Increasing The Serum Half-Life Of A Therapeutic Agent Targeting Complement C5ALEXION PHARMACEUTICALSAug 27, 2020
EP3222724
Further Novel Forms Of Interfering Rna MoleculesSILENCE THERAPEUTICSOct 31, 2018
EP1857547
Further Novel Forms Of Interfering Rna MoleculesATUGENAug 17, 2018
EP2258847
Futher Novel Forms Of Interfering Rna MoleculesSILENCE THERAPEUTICSOct 19, 2017

Latest patents of Alnylam Pharmaceuticals opposed by its competitors

Explore Alnylam Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3366775
Aug 6, 2025Modified Rnai Agents1
EP3656860
Apr 20, 2022Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use Thereof1
EP3105331
Jun 23, 2021Ketohexokinase (Khk) Irna Compositions And Methods Of Use Thereof1
EP2723758
Jun 20, 2018Angiopoietin-Like 3 (Angptl3) Irna Compostions And Methods Of Use Thereof1

Latest publications and patents of Alnylam Pharmaceuticals New

Explore the latest publications and patents granted to Alnylam Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Alnylam Pharmaceuticals

EP3366775
Aug 6, 2025Modified Rnai AgentsPatent Maintained As Amended
EP4573198
Jun 25, 2025Universal Non-Targeting Sirna Compositions And Methods Of Use ThereofRequest For Examination Was Made
EP3656860
Apr 20, 2022Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use ThereofGranted And Under Opposition
EP3105331
Jun 23, 2021Ketohexokinase (Khk) Irna Compositions And Methods Of Use ThereofGranted And Under Opposition
EP2723758
Jun 20, 2018Angiopoietin-Like 3 (Angptl3) Irna Compostions And Methods Of Use ThereofRevoked
EP2321414
Jan 10, 2018Enhancement Of Sirna Silencing Activity Using Universal Bases Or Mismatches In The Sense StrandNo Opposition Filed Within Time Limit

Latest PTAB cases involving Alnylam Pharmaceuticals

Discover the latest PTAB cases involving Alnylam Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 24, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Alnylam Pharmaceuticals

PGR2018-00088Jul 17, 2018ALNYLAM PHARMACEUTICALSSILENCE THERAPEUTICSTerminated-Settled
PGR2018-00089Jul 17, 2018ALNYLAM PHARMACEUTICALSSILENCE THERAPEUTICSTerminated-Settled
PGR2018-00075Jul 9, 2018ALNYLAM PHARMACEUTICALSSILENCE THERAPEUTICSTerminated-Settled
PGR2018-00067Jun 11, 2018ALNYLAM PHARMACEUTICALSSILENCE THERAPEUTICSTerminated-Settled
PGR2018-00059Apr 2, 2018ALNYLAM PHARMACEUTICALSSILENCE THERAPEUTICSTerminated-Settled

Peer Comparison New

IP litigation analysis comparing Alnylam Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ALNYLAM PHARMACEUTICALS445 -
GRUNECKER PATENT UND RECHTSANWALTE PARTG MBB48 - - -
SILENCE THERAPEUTICS28 - 5